Research Article

AI-Powered Literature Review for Pharmaceutical R&D

How AI tools accelerate systematic literature reviews in pharmaceutical R&D — covering regulatory requirements, multi-database search automation, evidence synthesis, and competitive intelligence for drug development teams.

Systematic literature reviews in pharma take 3-6 months and are required for regulatory submissions. AI tools can compress the search and screening phases by 40-60% while improving reproducibility — but human expert oversight remains non-negotiable.

In pharmaceutical R&D, literature reviews are not academic exercises. They are regulatory requirements. Every IND filing, every NDA submission, every post-marketing safety review depends on a comprehensive, reproducible survey of existing evidence. The FDA and EMA do not accept "we think we found everything." They expect documented, systematic search strategies with defensible inclusion and exclusion criteria.

The problem is that doing this well takes an enormous amount of time.

A standard systematic literature review for a pharmaceutical submission follows the PRISMA framework and typically spans 3-6 months:

Phase 1: Protocol Development (2-4 weeks) Define PICO criteria (Population, Intervention, Comparison, Outcome) Develop search strategies for each database (PubMed, Embase, Cochrane, Web of Science) Register the protocol (PROSPERO or internal registry)

Read next

  • Explore more on pharmaceutical
  • Explore more on literature-review
  • Explore more on systematic-review
  • Explore more on drug-discovery
  • Explore more on regulatory
Start freeSee Doxa

Related articles

AI Literature Review: How to Use AI to Write Better Literature Reviews in 2026 Learn how AI tools are transforming literature reviews. From paper discovery to synthesis, this guide covers AI-assisted systematic and narrative literature review workflows. How to Run a Systematic Literature Review with AI Agents A practical guide to using multi-agent systems for systematic reviews. Reduce the time from 12-18 months to weeks while maintaining PRISMA compliance. PapersFlow March 2026 Upgrade: Zero Entropy Search + GPT-5.4 Reasoning PapersFlow is now powered by Zero Entropy (YC W25) for 7x faster semantic search and GPT-5.4 for 33% fewer hallucinations. Here's what changed, why it matters, and how it affects your research workflow. Academic Research Databases: Complete List of 30+ Scholarly Databases (2026) Comprehensive guide to 30+ academic research databases organized by field. Coverage, pricing, and best use cases for Google Scholar, PubMed, Scopus, and more.

Explore PapersFlow

Research tools See the AI workflows PapersFlow supports. Compare PapersFlow Switching guides for Elicit, Zotero, Overleaf, and more. Use cases by field Find discipline-specific research workflows.

Frequently Asked Questions

Can AI-generated literature reviews be used in FDA submissions?
The FDA does not currently prohibit AI-assisted literature reviews, but the agency expects comprehensive, reproducible, and transparent search methodologies. Any AI-assisted review should document the tools used, search strategies employed, and screening criteria applied. Human expert review and validation of all AI outputs is essential. Always consult your regulatory affairs team before submitting AI-assisted evidence packages.
How does AI handle deduplication across multiple databases in systematic reviews?
AI tools use multi-layer deduplication: DOI matching (most reliable), title fuzzy matching (catches formatting variants), and author-year heuristics (catches papers indexed differently across databases). PapersFlow's DeepScan uses a 5-tier dedup strategy — DOI, external IDs, provider IDs, fuzzy title matching, and normalized title comparison — to eliminate duplicates from Semantic Scholar, OpenAlex, PubMed, and other sources.
What is the cost of a typical systematic literature review without AI assistance?
A traditional systematic review costs $50,000-$150,000 when accounting for researcher time (2-3 FTEs for 3-6 months), database access fees, and project management overhead. For pharmaceutical companies running 10-20 reviews per year across therapeutic areas, the annual cost can exceed $1 million. AI tools can reduce the labor-intensive search and screening phases, though expert synthesis and regulatory review remain manual.

Related articles